Camrelizumab in Combination with Rivoceranib (Apatinib) Sign

Camrelizumab in Combination with Rivoceranib (Apatinib) Significantly Prolonged Overall Survival and Progression-Free Survival vs. Sorafenib in Patients with Unresectable Hepatocellular Carcinoma in a Multinational Phase 3 Trial, a Joint Program with Elevar Therapeutics

Related Keywords

China , Paris , France General , France , South Korea , Republic Of Korea , Rivoceranib Apatinib , Hengrui Pharma , Elevar Therapeutics Inc , Crystalgenomics Inc , Jiangsu Hengrui Pharmaceuticals Co Ltd , Jiangsu Hengrui Pharmaceuticals Co , I Jiangsu Hengrui Pharmaceuticals Co Ltd , European Society For Medical Oncology , Significantly Prolonged Overall Survival , Progression Free Survival , Unresectable Hepatocellular Carcinoma , Multinational Phase , Joint Program , License Application , Francei September , European Society , Medical Oncology , Response Evaluation Criteria , Solid Tumors , Hepatocellular Carcinoma , Orphan Drug Designation , Elevar Therapeutics , Pharma Exec , Jiangsu Hengrui Pharmaceuticals , Biologics , Antibodies , Therapeutic Antibodies , Recombinant , Antibody Drug Conjugates , Dc , Immunoconjugates , Biosimilar Antibodies , Biosuperior Antibodies , Antibody Fragments , Scfv , Lab , Nanobodies , Domain Antibodies , Manufacturing ,